Swerdlow Charles D
Cedars-Sinai Medical Center, Los Angeles, USA.
Arrhythm Electrophysiol Rev. 2017 Apr;6(1):19-20. doi: 10.15420/aer.2017.6.1:PP8.
Mark Josephson dedicated his career to the prevention of premature sudden cardiac death (SCD). Toward that goal, he was an early adopter of the implantable cardioverter defibrillator (ICD) and indefatigable advocate for better ICD technology,[1] both as a clinical tool and as living laboratory to study SCD in ambulatory patients. With characteristic intellectual integrity and analytical rigour, he sought an honest and balanced appraisal of the life-saving benefits and serious complications of this unique therapy.
马克·约瑟夫森将他的职业生涯奉献给了预防过早心脏性猝死(SCD)。为了实现这一目标,他是植入式心脏复律除颤器(ICD)的早期使用者,也是更好的ICD技术的不懈倡导者,[1] 既将其作为一种临床工具,也作为研究门诊患者SCD的活体实验室。凭借其特有的知识完整性和分析严谨性,他寻求对这种独特疗法的救命益处和严重并发症进行诚实而平衡的评估。